by Admin | May 23, 2024 | Portfolio News
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development...
by Admin | Apr 9, 2024 | Portfolio News
SAN DIEGO, CA & SHANGHAI, April 1st, 2024 – Sirius Therapeutics today announced it has dosed the first subject in a Chinese Phase 1 trial of SRSD107, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and...
by Admin | Apr 9, 2024 | Portfolio News
SAN DIEGO, April 8, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has...
by Admin | Mar 27, 2024 | Portfolio News
Financing includes nine new investors and was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN...
by Admin | Feb 28, 2024 | Portfolio News
–Company Receives Five-year Exclusivity Extension Through GAIN Act — SAINT-LOUIS, France & WEILL AM RHEIN, Germany, February 27,2024 – Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic...
by Admin | Nov 9, 2023 | Portfolio News
Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive...